X
Xingying Biotechnology
Allows live cell drugs eliminate cancer cells
About Xingying Biotechnology
Neukio Biotherapeutics is a pioneering company in the field of biotechnology, specializing in the development of iPSC-derived CAR-NK cell therapies for cancer treatment. The company operates in the biopharmaceutical market, focusing on creating advanced immunotherapies that leverage the natural abilities of NK (Natural Killer) cells to target and destroy cancer cells. Neukio's primary clients include healthcare providers, research institutions, and pharmaceutical companies seeking cutting-edge cancer treatment solutions.
The business model of Neukio Biotherapeutics revolves around research and development, clinical trials, and eventual commercialization of their proprietary CAR-NK cell therapies. Revenue is generated through partnerships, licensing agreements, and direct sales of their therapeutic products once they receive regulatory approval.
Neukio Biotherapeutics aims to revolutionize cancer treatment by offering innovative, effective, and safe immunotherapy options. The company has secured significant funding to support its research and development efforts, ensuring continuous advancement in their technology platform.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2022 | $50M | $200M | IDG Capital · CD Capital · Yahui Investment · Kuanyu Capital | ↗ |
| EARLY VCOther financing | Jul 2021 | $40M | $160M | Lilly Asia Ventures | ↗ |
Growth signals
Latest recorded traffic for Xingying Biotechnology is 2.2K monthly website visits, up 197.3% over the last three months. Xingying Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xingying Biotechnology in its local ecosystem
The Xingying Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Lilly Asia Ventures
IDG Capital
CD Capital- YIYahui Investment
- KCKuanyu Capital
Eli Lilly
Sherpa Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xingying Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xingying Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









